The Global Immuno-oncology Drugs Market by Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy), by Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers), and by Region was valued at US$ 43,084.5 million in 2016 and is projected to exhibit a CAGR of 14.9% over the forecast period (2017 – 2025), as highlighted in a new report published by Coherent Market Insights. Increasing prevalence of cancer is expected to boost the demand for immune-oncology drugs. Also, innovative product launches along with robust pipeline is expected to boost the growth of immune-oncology drugs market growth over the forecast period. Major manufacturers are investing into R&D to develop immune-oncology therapies by understanding tumor functions and ways to counter them.
Request for a sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/1271
Research and development by leading as well as small and mid-sized players in immuno-oncology drugs market is expected to support growth of the global immuno-oncology drugs market. In January 2018, Feldan Therapeutics and Green Cross LabCell Collaborated to develop Natural Killer Cell-based Immunotherapies. In January 2018, OBI Pharma initiated Phase 1 Trial of immunotherapy candidate OBI-888 in advanced solid tumor patients. Furthermore, in January 2018, Keytruda, developed by Merck & Co. reported slow liver cancer progression in Phase 2 trial. Immuno-oncology combination therapies are also under research for various cancer indications. In January 2018, the U.S. Food & Drug Administration granted breakthrough therapy status to Lenvima-Keytruda combo for advanced kidney cancer. Furthermore, in February 2018, Opdivo-Yervoy combination therapy showed delayed disease progression in patients with advanced non-small cell lung cancer. Genentech combination therapy Tecentriq and Avastin delayed kidney cancer progression in Phase III trials in December 2017. AstraZeneca Plc’s Imfinzi (Durvalumab) showed delayed non-small cell lung cancer progression in Phase III trials in November 2017.
Browse 25 Market Data Tables and 38 Figures spread through 171 Pages and in-depth TOC on Global Immuno-Oncology Drugs Market By Drug Type,( Immune Checkpoint Inhibitors (CTL-4 Checkpoint Inhibitor, and PD-1 & PD-L1 Checkpoint Inhibitor), Monoclonal Antibodies (Naked, Conjugated, and Bispecific), Cytokine-Based Immunotherapy (Intron A and Proleukin), Cancer Vaccines (Preventive Vaccines and Treatment Vaccines), and CAR-T Cell Therapy (Kymriah and Yescarta)), By Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) – Global Forecast to 2025
Manufacturers are focusing on upgrading the available immune-oncology drugs as well as developing new immune-oncology drugs for cancer treatment. For instance, AstraZeneca’s Durvalumab (Imfinzi) was approved in 2017, as immune checkpoint inhibitor, which blocks interaction of PD-L1 with PD-1 and CD80. In December 2017, Bristol-Myers Squibb received approval for Nivolumab (Opdivo) in adjuvant treatment of melanoma. In August 2017, Novartis received approval for CAR-T therapy named Kymriah for children and young adult with B- cell lymphoblastic lymphoma. Gilead Life Science completed the acquisition of Kite pharma Ltd. in October 2017, and Gilead’s CAR-T therapy Yescarta received the U.S. Food & Drug Administration (FDA) approval in October 2017 to treat non-Hodgkin lymphoma. Celgene Corporation, in January 2018, announced acquisition of Juno Therapeutics, Inc. Through this acquisition, Celgene Corporation will gain access to novel CAR-T therapy, which is in pipeline of Juno Therapeutics. Furthermore, Amgen, Inc. received FDA approval, for Imlygic in 2017, which is an oncolytic virus to treat melanoma. In March 2017, Avelumab (Bavencio), jointly developed by EMD Serono, and Pfizer, Inc. received FDA approval for the treatment of metastatic merkel cell carcinoma.
Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/1271
Key Takeaways of the Global Immuno-Oncology Drugs Market:
The global immuno-oncology drugs market is expected to exhibit a CAGR of 14.9% over the forecast period. This is attributed to presence of number of leading manufacturers who are focusing on bringing out innovative therapies through extensive research and development such as Bristol Myers Squibb, Novartis, and Pfizer, Inc.
Biopharmaceutical companies are developing a robust pipeline of immune-oncology therapies due to increasing demand for the same. The U.S. Food & Drug Administration has approved a number of immune checkpoint inhibitors including Yervoy (anti-CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1).
Research partnerships and collaborations to develop new drugs by various market players is supporting the growth of the market. as competitors would strive to gain competitive edge
Major players operating in the global immuno-oncology drugs market include Amgen, Inc. AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, AbbVie, Inc., Pfizer Inc., Sanofi S.A., EMD Serono, Inc., Gilead Sciences Inc., Prometheus Therapeutics & Diagnostics, Aduro BioTech, Galena Biopharma, Bavarian Nordic, Celldex Therapeutics, ImmunoCellular Therapeutics, and Incyte